Compare REAL & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | REAL | ENGN |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | Canada |
| Employees | N/A | 82 |
| Industry | Other Specialty Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 115.9M |
| IPO Year | 2019 | N/A |
| Metric | REAL | ENGN |
|---|---|---|
| Price | $9.20 | $1.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $17.00 | ★ $21.08 |
| AVG Volume (30 Days) | ★ 3.9M | 3.2M |
| Earning Date | 05-07-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.55 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $692,845,000.00 | N/A |
| Revenue This Year | $14.30 | N/A |
| Revenue Next Year | $10.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.38 | N/A |
| 52 Week Low | $4.71 | $1.40 |
| 52 Week High | $17.39 | $12.25 |
| Indicator | REAL | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 38.92 | 26.94 |
| Support Level | $8.05 | $1.40 |
| Resistance Level | $11.48 | $9.16 |
| Average True Range (ATR) | 0.69 | 0.28 |
| MACD | -0.21 | -0.13 |
| Stochastic Oscillator | 10.64 | 3.49 |
The RealReal Inc is an online marketplace for authenticated, resale luxury goods, providing an end-to-end service that unlocks supply and creates a trusted, curated marketplace for buyers globally. Since its inception, the company has cultivated a loyal and engaged consignor and buyer base through continuous investment in its technology platform, logistics infrastructure, brand and people. It offers a wide selection of authenticated, mainly pre-owned luxury goods bearing the brands of thousands of luxury and premium designers, including Cartier, Chanel, Christian Dior, Gucci, Hermes, Louis Vuitton and Rolex. The company offers products across women's fashion, men's fashion, jewelry, and watches, promoting the recirculation of luxury goods and contributing to a more sustainable world.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.